The Research of Hyaluronic Acid Functionalized Mesoporous Silica Nanoparticles MCM-41 Loading Paclitaxel for SMMC-7721 Liver Cancer Cells
- Author:
Zhe MA
1
Author Information
- Publication Type:Journal Article
- Keywords: Hysluronic acid; Mesoporous silica; Paclitaxel; SMMC-7721 hepatocillular carcinoma cell; Tumor
- From: Chinese Pharmaceutical Journal 2019;54(2):110-116
- CountryChina
- Language:Chinese
- Abstract: OBJECTIVE: To establish a drug delivery system based on hyaluronic acid functionalized mesoporous silica nanoparticles MCM-41 loaded with paclitaxel (HA-MCM-41-PTX). The physical and chemical properties, in vitro drug release and the antitumor effect were investigated. METHODS: The morphological structure and particle size of MCM-41 were observed by TEM. The drug delivery system was characterized by PXRD and FTIR. The in vitro release experiments was carried out to investigate the dissolution rate of HA-MCM-41-PTX. The in vitro cells experiment was carried out to explore the mechanism of HA-MCM-41-PTX on cells. RESULTS: The drug loading capacity of HA-MCM-41-PTX was 28.75%. The in vitro drug release experiments showed that HA-MCM-41-PTX exhibited controlled release with a cumulative release of (86.19±5.11)% until 48 h. In vitro cell experiments showed that HA-MCM-41-PTX had excellent targeting effect due to the modification of hyaluronic acid, which was easier to be uptaken by cells and exhibited great antitumor effect. CONCLUSION: HA-MCM-41-PTX is an excellent drug delivery system with both controlled release and targeting antitumor effect.
